FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1552-1554 October 11, 2007 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Early reperfusion therapy for myocardial infarction has transformed the treatment of this disease. The restoration of blood flow to the heart within hours after thrombotic coronary occlusion reduces infarct size, maintains cardiac function, and minimizes the risk of late heart failure and lethal arrhythmias. However, high success rates of coronary reperfusion, coupled with aggressive efforts to shorten the time from the manifestation of symptoms to the restoration of arterial blood flow, have brought us close to the practical limits of acute revascularization therapy for myocardial infarction.

Recent work by Kuhn et al.¹ underscores the influence of postinfarction cellular and molecular . . . [Full Text of this Article]

Source Information

From the Center for Molecular Cardiovascular Research, University of Cincinnati, Cincinnati.

This article has been cited by other articles:

• Sarwar, R., Cook, S. A. (2009). Genomic Analysis of Left Ventricular Remodeling. Circulation 120: 437-444 [Full Text]